iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Medicamen Biotech announces debut in domestic pharma sector

4 Oct 2022 , 03:08 PM

Medicamen Biotech Limited, a pharmaceutical company, is expanding into the domestic market through its subsidiary Medicamen Life Sciences Pvt Ltd.

Medicamen group chairman Rahul Bishnoi stated in a press release, "The Company's Vision is to become a most admired Pharmaceutical organisation by offering research & data backed, affordable & quality medicines for the Indian population. To begin with, the company has entered the cardio-vascular & Diabetes (CVD) Business, which contributes annual revenue of more than Rs50,000 crore to IPM with a CAGR of 11%."

Kamal Pahwa, a Pharma Veteran with 32 Years of Experience in the CVD Business, and Pramod Sharma of Neelkanth Drugs Pvt Ltd, India's top distribution network, have joined forces with Medicamen to establish this extremely ambitious initiative, stated Bishnoi.

Medicamen Biotech was founded in 1996 and has since focused on worldwide commerce. It has just started its state-of-the-art oncology factory in Haridwar, which is intended for regulated markets like the United States and Europe. Medicamen released its high-quality cancer drugs in the home market early this year.

At around 12.10 PM, Medicamen Biotech was trading at Rs1,002.60 per piece, up by 0.98% from its previous closing of Rs992.90 on the BSE. The scrip touched intraday high and low of Rs1,024.15 and Rs1,000.90 respectively. 

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Medicamen Biotech
  • Medicamen Biotech Domestic Market
  • Medicamen Biotech News
  • Medicamen Biotech Share
  • Medicamen Biotech Share Price
  • Medicamen Biotech Subsidiary
  • Medicamen Biotech Updates
sidebar mobile


Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.